FDA Orange Book
Is there a generic for Zokinvy?
Zokinvy contains lonafarnib. Orange Book status for every listed strength, the approved generic makers, and the listed patents and exclusivities.
Source: FDA Orange Book data file dated 2026-10-09. Publisher page
No. The Orange Book lists no active FDA-approved generic (ANDA) for Zokinvy (lonafarnib). The Orange Book shows its last listed patent expires July 26, 2029 and its last listed exclusivity ends November 20, 2027.
Run it in Rivvi
Map Zokinvy and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Zokinvy products in the Orange Book
| Form and route | Strength | Brand status | Brand TE | Active generics | Generic TE codes |
|---|---|---|---|---|---|
| capsule, oral | 50MG | Marketed (Rx) | None | 0 | None |
| capsule, oral | 75MG | Marketed (Rx) | None | 0 | None |
NDA 213969, held by SENTYNL THERAPEUTICS INC. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.
Zokinvy patents
| Patent | Expires | Covers | Use code | NDA |
|---|---|---|---|---|
| 7838531 | July 26, 2029 | Method of use | U-3070 | 213969 |
Zokinvy exclusivity
| Code | Meaning | Expires | NDA |
|---|---|---|---|
| ODE-324 | Orphan drug exclusivity | November 20, 2027 | 213969 |
Zokinvy NDC codes
Questions
Is there a generic for Zokinvy?
No. The Orange Book lists no active FDA-approved generic (ANDA) for Zokinvy (lonafarnib). The Orange Book shows its last listed patent expires July 26, 2029 and its last listed exclusivity ends November 20, 2027.
What is the generic name for Zokinvy?
The active ingredient in Zokinvy is lonafarnib, per the FDA Orange Book.
When does the Zokinvy patent expire?
The last patent listed for Zokinvy in the Orange Book expires July 26, 2029. A listed patent expiry date is not a generic launch date.
What does a therapeutic equivalence code mean?
In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.